Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down101.000 -2.300 (-2.227%)
Research Report

27/01/2021 17:13

{I-bank focus}Macquarie starts JD Health (06618) at HK$193

[ET Net News Agency, 27 January 2021] Macquarie Research initiated coverage on JD
Health (JDH) (06618) with an "outperform" rating and target price of HK$193.
The research house sees higher growth visibility for the e-commerce companies versus
policy-dependent online medical services. JDH, as an industry leader, has ample growth
drivers to leverage, improving profitability, more affluent customers, and an impressive
management team.
Macquarie forecasted JDH's overall revenue to grow at a 56% CAGR during 2020-23, while
it estimated the overall adj OPM will improve from 4.6% in 2020 to 8.7% in 2023,
reflecting e-commerce core operating profit growth at a 99% CAGR in 2020-23, primarily
attributable to economies of scale. (KL)

Remark: Real time quote last updated: 23/07/2021 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.